These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

884 related items for PubMed ID: 26832847

  • 1. Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.
    Barbui T, Thiele J, Vannucchi AM, Tefferi A.
    Blood Cancer J; 2015 Aug 14; 5(8):e337. PubMed ID: 26832847
    [Abstract] [Full Text] [Related]

  • 2. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ, Bernema Z, Van Bockstaele D, De Raeve H, Schroyens W.
    Pathol Biol (Paris); 2007 Mar 14; 55(2):92-104. PubMed ID: 16919893
    [Abstract] [Full Text] [Related]

  • 3. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
    Hussein K, Bock O, Theophile K, von Neuhoff N, Buhr T, Schlué J, Büsche G, Kreipe H.
    Exp Hematol; 2009 Oct 14; 37(10):1186-1193.e7. PubMed ID: 19616600
    [Abstract] [Full Text] [Related]

  • 4. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ, Berneman Z, Schroyens W, De Raeve H.
    Acta Haematol; 2015 Oct 14; 133(1):36-51. PubMed ID: 25116092
    [Abstract] [Full Text] [Related]

  • 5. Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice.
    Tefferi A, Barbui T.
    Mayo Clin Proc; 2015 Sep 14; 90(9):1283-93. PubMed ID: 26355403
    [Abstract] [Full Text] [Related]

  • 6. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.
    Rumi E, Cazzola M.
    Blood; 2017 Feb 09; 129(6):680-692. PubMed ID: 28028026
    [Abstract] [Full Text] [Related]

  • 7. Essential thrombocythemia vs. early/prefibrotic myelofibrosis: why does it matter.
    Barosi G.
    Best Pract Res Clin Haematol; 2014 Jun 09; 27(2):129-40. PubMed ID: 25189724
    [Abstract] [Full Text] [Related]

  • 8. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
    Vytrva N, Stacher E, Regitnig P, Zinke-Cerwenka W, Hojas S, Hubmann E, Porwit A, Bjorkholm M, Hoefler G, Beham-Schmid C.
    Arch Pathol Lab Med; 2014 Sep 09; 138(9):1203-9. PubMed ID: 25171702
    [Abstract] [Full Text] [Related]

  • 9. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
    Tefferi A, Barbui T.
    Am J Hematol; 2017 Jan 09; 92(1):94-108. PubMed ID: 27991718
    [Abstract] [Full Text] [Related]

  • 10. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
    Schwarz J, Penka M, Campr V, Pospísilová D, Kren L, Nováková L, Bodzásová C, Brychtová Y, Cerná O, Dulícek P, Joniásová A, Kissová J, Korístek Z, Schützová M, Vonke I, Walterová L.
    Vnitr Lek; 2011 Feb 09; 57(2):189-213. PubMed ID: 21416861
    [Abstract] [Full Text] [Related]

  • 11. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
    Kim SY, Im K, Park SN, Kwon J, Kim JA, Lee DS.
    Am J Clin Pathol; 2015 May 09; 143(5):635-44. PubMed ID: 25873496
    [Abstract] [Full Text] [Related]

  • 12. The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
    Thiele J, Kvasnicka HM.
    Curr Hematol Malig Rep; 2009 Jan 09; 4(1):33-40. PubMed ID: 20425436
    [Abstract] [Full Text] [Related]

  • 13. Bone marrow histopathology and biological markers as specific clues to the differential diagnosis of essential thrombocythemia, polycythemia vera and prefibrotic or fibrotic agnogenic myeloid metaplasia.
    Michiels JJ.
    Hematol J; 2004 Jan 09; 5(2):93-102. PubMed ID: 15048058
    [Abstract] [Full Text] [Related]

  • 14. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
    Brière J.
    Bull Acad Natl Med; 2007 Mar 09; 191(3):535-48. PubMed ID: 18072652
    [Abstract] [Full Text] [Related]

  • 15. Molecular genetic evaluation of myeloproliferative neoplasms.
    Azzato EM, Bagg A.
    Int J Lab Hematol; 2015 May 09; 37 Suppl 1():61-71. PubMed ID: 25976962
    [Abstract] [Full Text] [Related]

  • 16. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.
    Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, Barosi G, Verstovsek S, Birgegard G, Mesa R, Reilly JT, Gisslinger H, Vannucchi AM, Cervantes F, Finazzi G, Hoffman R, Gilliland DG, Bloomfield CD, Vardiman JW.
    Blood; 2007 Aug 15; 110(4):1092-7. PubMed ID: 17488875
    [Abstract] [Full Text] [Related]

  • 17. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy.
    Tefferi A.
    Am J Hematol; 2008 Jun 15; 83(6):491-7. PubMed ID: 18429051
    [Abstract] [Full Text] [Related]

  • 18. Prognostic factors and models in polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
    Passamonti F.
    Clin Lymphoma Myeloma Leuk; 2011 Jun 15; 11 Suppl 1():S25-7. PubMed ID: 22035744
    [Abstract] [Full Text] [Related]

  • 19. The differential diagnosis of classical myeloproliferative neoplasms (MPN): the updated WHO criteria.
    Kvasnicka HM.
    Rinsho Ketsueki; 2019 Jun 15; 60(9):1166-1175. PubMed ID: 31597840
    [Abstract] [Full Text] [Related]

  • 20. Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018.
    Mejía-Ochoa M, Acevedo Toro PA, Cardona-Arias JA.
    BMC Cancer; 2019 Jun 17; 19(1):590. PubMed ID: 31208359
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.